The Drug Enforcement Administration (DEA) announced plans to temporarily place 7-hydroxymitragynine (7-OH), a potent opioid-like compound derived from kratom, into Schedule I of the Controlled Substances Act. This action follows FDA recommendations and reflects growing concerns about the substance's health risks, which mirror those of powerful opioids like heroin.

What Is 7-OH and How Does It Differ From Regular Kratom?

7-OH is a concentrated extract from kratom, a tropical tree native to Southeast Asia. While kratom itself has been used for centuries in its native region, where people chew fresh leaves or brew tea, 7-OH products are highly concentrated versions that contain levels of the compound far exceeding what occurs naturally. This distinction matters because concentrated 7-OH produces opioid-like effects considerably stronger than traditional kratom.

Despite lacking FDA approval for any medical use, 7-OH is widely promoted for pain relief, mood enhancement, and relaxation. The compound acts on the brain's mu-opioid receptors, the same targets that powerful prescription opioids affect. Because of this mechanism, 7-OH can produce serious side effects, particularly when taken in high doses or combined with other substances.

Why Is the DEA Taking Action Now?

Federal officials cited increasing reports of 7-OH misuse, dependence, and overdose as the primary reason for the emergency scheduling. Health officials have documented rising poison center calls, emergency department visits, and overdose cases involving 7-OH products. The FDA also noted that many of these products contain inconsistent concentrations, inaccurate labeling, and undisclosed ingredients, making it impossible for consumers to know exactly how much active drug they are ingesting.

The widespread availability of 7-OH has outpaced understanding of its dangers. Products are sold over the counter in convenience stores, smoke and vape shops, and online retailers with minimal age restrictions or safety safeguards. This accessibility, combined with aggressive marketing as a safe herbal supplement, has created a public health concern that regulators can no longer ignore.

What Are the Health Risks Associated With 7-OH?

Because 7-OH acts directly on opioid receptors in the brain, it can produce many of the same harmful effects associated with prescription opioids and illicit drugs. Users have reported experiencing:

• Respiratory Depression: Slowed or shallow breathing, which can become life-threatening at high doses or when combined with other central nervous system depressants
• Sedation and Impaired Judgment: Drowsiness and reduced cognitive function that can impair daily functioning and decision-making
• Gastrointestinal Issues: Nausea, vomiting, and other digestive problems that can occur during use or withdrawal
• Tolerance Development: The body adapts to the drug, requiring higher doses to achieve the same effect, increasing overdose risk
• Dizziness: Balance and coordination problems that increase the risk of falls and injuries

Perhaps most concerning is that withdrawal symptoms emerge after prolonged use. People who stop using 7-OH after regular consumption report anxiety, insomnia, irritability, and gastrointestinal distress, similar to opioid withdrawal. This pattern of dependence and withdrawal mirrors what happens with prescription opioids, suggesting that 7-OH carries comparable addiction potential.

How Long Will the Ban Last and What Does It Mean?

The temporary Schedule I placement would remain in effect for two years, with a possibility of a one-year extension. During this period, the manufacture, distribution, and possession of 7-OH products would be subject to strict drug control laws. The ban would apply to any 7-OH product containing at least 0.05% 7-OH by dry weight or more than 1 milligram of 7-OH. This temporary measure gives researchers time to evaluate the compound's pharmacological properties and health risks more thoroughly.

What Treatment Options Exist for 7-OH Dependence?

For people struggling with 7-OH use or dependence, treatment approaches mirror those used for opioid use disorder and are tailored to the severity of symptoms. Individuals with mild substance dependence may benefit from outpatient treatment that includes psychotherapy, such as cognitive behavioral therapy and motivational interviewing, along with participation in peer support groups.

Those experiencing severe dependence, co-occurring mental health issues, or significant withdrawal symptoms may require inpatient treatment that provides 24-hour support. In some cases, treatment includes medications commonly used to treat opioid use disorder, such as buprenorphine or methadone, to reduce withdrawal symptoms and cravings.

Steps to Take If You or Someone You Know Is Struggling With 7-OH

• Recognize the Signs: Be aware that 7-OH dependence can develop after regular use, and withdrawal symptoms like anxiety, insomnia, and irritability may indicate a problem requiring professional help
• Seek Professional Assessment: Contact a treatment provider or visit a rehab directory to determine whether outpatient or inpatient treatment is appropriate for your specific situation
• Explore Medication-Assisted Options: Ask your healthcare provider about medications like buprenorphine or methadone, which can reduce cravings and withdrawal symptoms during recovery
• Engage in Behavioral Therapy: Participate in cognitive behavioral therapy or motivational interviewing to address the underlying factors driving use and develop coping strategies

What Is the Broader Context for This Action?

The DEA's move to ban 7-OH comes as federal agencies intensify efforts to address addiction and overdose across the country. The Substance Abuse and Mental Health Services Administration (SAMHSA) announced more than $281 million in funding for 15 grant programs aimed at expanding access to substance use disorder treatment, overdose prevention, and recovery support services. This includes $68.2 million specifically for medication-assisted treatment grants that expand access to medications for opioid use disorder.

The coordinated response reflects a recognition that addiction takes many forms and that emerging substances like concentrated 7-OH require swift regulatory action alongside expanded treatment capacity. By temporarily scheduling 7-OH while simultaneously investing in treatment infrastructure, federal agencies are attempting to address both the supply side and the demand side of the addiction crisis.

If you or someone you know is struggling with substance use, help is available. The SAMHSA National Helpline is free, confidential, and available 24/7 by calling or texting 988, or by visiting 988lifeline.org.